

# High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease

著者 (英)	Kenichi Makishima, Naoshi OBARA, Kantaro Ishitsuka, Shinichiro Sukegawa, Sakurako Suma, Yusuke Kiyoki, Naoko Baba, Tatsuhiro Sakamoto, Takayasu KATO, Manabu KUSAKABE, Hidekazu NISHIKII, Naoki KURITA, Yasuhisa YOKOYAMA, Mamiko SAKATA-YANAGIMOTO, Yuichi HASEGAWA, Shigeru CHIBA
journal or publication title	Annals of hematology
volume	98
number	4
page range	1031-1032
year	2018-04
権利	(C) Springer-Verlag GmbH Germany, part of Springer Nature 2018 The final publication is available at <a href="https://doi.org/10.1007/s00277-018-3521-4">https://doi.org/10.1007/s00277-018-3521-4</a>
URL	<a href="http://hdl.handle.net/2241/00155639">http://hdl.handle.net/2241/00155639</a>

doi: 10.1007/s00277-018-3521-4

LETTER

**High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease**

Kenichi Makishima, Naoshi Obara, Kantaro Ishitsuka, Shinichiro Sukegawa, Sakurako Suma, Yusuke Kiyoki, Naoko Baba, Tatsuhiro Sakamoto, Takayasu Kato, Manabu Kusakabe, Hidekazu Nishikii, Naoki Kurita, Yasuhisa Yokoyama, Mamiko Sakata-Yanagimoto, Yuichi Hasegawa, Shigeru Chiba

Department of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan

**Running title:** High efficacy of eculizumab for cold agglutinin disease

Corresponding author: Naoshi Obara, M.D., Ph.D. Department of Hematology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan. Phone: +81-29-853-3127, Fax: +81-29-853-8079, email: n-obara@md.tsukuba.ac.jp

Main text: 497 words

Figure: 1

*Dear Editor:*

Cold agglutinin disease (CAD) is characterized by immunoglobulin M (IgM)-mediated hemagglutination in cold conditions and complement activation leading to extra- and intravascular hemolysis [1, 2]. Under conditions like infection, complement activation persists and intravascular hemolysis occurs by the formation of membrane attack complex (MAC). Therefore, eculizumab, an anti-C5 antibody is expected to be effective in suppressing hemolytic attacks in CAD.

Herein, we report a case of fulminant type primary CAD treated with eculizumab.

A 39-year-old man was diagnosed with bacterial pneumonia by a family doctor and treated with antibiotics. Five days after the diagnosis, he was referred to our hospital on account of hemoglobinuria, malaise, hemolytic anemia, and acute kidney injury. He had severe anemia (Hb 5.2 g/dL), increased indirect bilirubin (3.6 mg/dL) and lactate dehydrogenase (LDH, 4347 IU/L) levels, decreased haptoglobin (<10 mg/dL) concentration, renal dysfunction (serum creatinine 2.99 mg/dL), and hemoglobinuria. Due to severe hemolysis and clotting of blood, red blood cell and reticulocyte counts could not accurately be assessed. In a direct Coombs test, only complement Coombs test yielded positive results. Paroxysmal nocturnal hemoglobinuria (PNH)-type cells were not detected. Serum cold agglutinin titers were markedly elevated (> 8192 folds).

Based on the diagnosis of fulminant hemolytic crisis in CAD caused by bacterial pneumonia, we initiated heat retention, blood transfusion, and steroid administration, but the

hemolysis did not improve. Due to the worsening renal function, further increasing LDH level (>7000 IU/L), and rapidly deteriorating general condition in a few days, the decision was made to commence eculizumab at 900 mg once a week (Fig. 1). After the initial administration, rapid reduction in the LDH level and improvement in hemolysis were observed, and most of the laboratory data were normalized including serum creatinine levels one month after initiation of eculizumab. Although there were no decreases in agglutinin titers, eculizumab treatment was terminated after the fourth shot because of the stabilization of hemolysis and the marked improvement in general condition. Since then, the observation period has been more than ten months; cold agglutinin titers were decreased, and hemolysis has not recurred.

Recently, the effectiveness of combination therapy using rituximab and bendamustine for the treatment of CAD has been reported [3]. However, a period of several months is required before the effect is noticeable, and immediate changes cannot be expected. Eculizumab is an antibody that specifically binds to the C5 complement protein and prevents intravascular hemolysis [4-6]. Theoretically, eculizumab is also expected to be effective for the treatment of hemolytic attacks in CAD. Although there are no clinical trials, its potential efficacy has been suggested in some case reports [7-9]. In the current case, complement activation triggered by pneumonia led to fulminant hemolytic anemia. Because renal failure and hemolysis progressed rapidly in our case, eculizumab was administered instead of rituximab. Suppression of complement activity by eculizumab was clear, which resulted in the reversal of the patient's critical condition and rapid clinical remission. It is likely that hemolytic attacks in CAD are a good target of eculizumab, as anticipated.

## **Figure Legend**

Fig.1 Effect of eculizumab in a patient with fulminant hemolytic anemia of primary cold agglutinin disease. PSL, prednisolone; LDH, lactate dehydrogenase; RBC, red blood cell; sCre, serum creatinine; \*, Cold agglutinin titers were saturated over 8192-fold.

## **Notes**

### **Compliance with ethical standards**

### **Conflict of interest**

The authors declare that they have no conflict of interest.

### **Informed consent**

Written informed consent was obtained from the patient.

## **References**

1. Berentsen S, Tjønnfjord GE. Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia. *Blood Reviews* 2012;26:107-115.

<https://doi.org/10.1016/j.blre.2012.01.002>

2. Berentsen S, Ulvestad E, Langholm R, Beiske K, Hjorth-Hansen H, Ghanima W, et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. *Haematologica* 2006;91:460–466.

3. Berentsen S, Randen U, Oksman M, Birgens H, Tvedt THA, Dalgaard J et al. Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial. *Blood* 2017;130:537-541. <https://doi.org/10.1182/blood-2017-04-778175>
4. Wong EK, Kavanagh D. Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. *Transl Res* 2015;165:306-320. <https://doi.org/10.1016/j.trsl.2014.10.010>
5. Hillmen P, Hall C, Marsh JC, Elebute M, Bombara MP, Petro BE, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. *N Engl J Med* 2004;350:552-559. <https://doi.org/10.1056/NEJMoa031688>
6. Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muus P, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. *N Engl J Med* 2006;355:1233-1243. <https://doi.org/10.1056/NEJMoa061648>
7. Shapiro R, Chin-Yee I, Lam S. Eculizumab as a bridge to immunosuppressive therapy in severe cold agglutinin disease of anti-Pr specificity. *Clin Case Rep* 2015;3:942–944. <https://doi.org/10.1002/ccr3.399>
8. Roth A, Hüttmann A, Rother RP, Dührsen U, Philipp T. Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease. *Blood* 2009;113:3885-3886. <https://doi.org/10.1182/blood-2009-01-196329>

9. Gupta N, Wang ES. Long-term response of refractory primary cold agglutinin disease to eculizumab therapy. *Ann Hematol* 2014;93:343-344. <https://doi.org/10.1007/s00277-013-1800-7>

Figure 1

